How much do treatments for dryness cost and what’s included?
How much do treatments for dryness cost and what’s included? Costs vary by pathway and whether you need foundations (moisturiser, lubricants), local vaginal oestrogen or DHEA, pelvic floor physio, and optional procedures (laser/radiofrequency or injectables like PRP/polynucleotides). Most plans start with an assessment, conservative care and review; procedures, if needed, are typically packaged with follow-up. See our pricing page for itemised inclusions. Educational only. Results vary. Not a cure.
Detailed Medical Explanation
How much do treatments for dryness cost and what’s included? Your total spend depends on what’s driving your genitourinary syndrome of menopause (GSM)—also called vaginal atrophy—and which steps you need to feel comfortable. Most people respond to a foundation-first plan: a scheduled vaginal moisturiser, the right personal lubricant (water-based for versatility and condoms; silicone-based for longest glide at a tender vestibule; oil-based feels rich but may degrade latex condoms/toys), and, if acceptable, local vaginal oestrogen or vaginal DHEA. Some also benefit from pelvic health physiotherapy to address guarding, and a minority choose adjunct procedures (vaginal laser/radiofrequency or injectables such as platelet-rich plasma and polynucleotides) for targeted support.
What an assessment typically includes. A structured history screens for dryness, dyspareunia, urinary urgency/frequency, and common mimics (BV, thrush, UTI, contact dermatitis, lichen sclerosus). We check red flags (e.g., new post-menopausal bleeding) and map where pain is worst—often the vestibule/posterior fourchette. You’ll receive a personalised starter plan (moisturiser schedule, lubricant choice, placement technique), and if appropriate, a prescription for local therapy. Review is built in to judge real-life changes (urine-sting, micro-tears, speculum tolerance).
How foundations influence cost. Non-prescription moisturisers and lubricants are modest ongoing costs, but they reduce friction immediately and often prevent the need for procedures. If you use local oestrogen/DHEA, costs relate to product and dosing; many people stabilise on a lowest effective maintenance schedule after the first 2–6 weeks of building benefit.
When procedures come into the picture. Energy-based treatments (vaginal laser/radiofrequency) and regenerative injectables (PRP/polynucleotides) are adjuncts—considered when a well-run foundation + local therapy plan still leaves symptoms. Clinics usually price these as a short series (often 2–3 sessions spaced 4–8 weeks apart) with a follow-up to evaluate day-to-day outcomes (fewer “paper-cut” splits, easier penetration, calmer walking/cycling). Because results are not permanent, some people later choose a single maintenance visit; others maintain comfort with foundations alone.
What’s typically included in a package. Transparent packages usually outline: pre-treatment review and consent; the procedure itself; post-care supplies/leaflets; and a >6–12 week review. Good plans also cover what happens if you need to pause (e.g., for infection) and whether rescheduling/review fees apply. For a plain-English summary of the steps we follow, see how treatment steps are sequenced, and for itemised costs and inclusions see treatment prices.
Value comes from fit, not from doing more. Because GSM mixes biology (low oestrogen → thinner epithelium, higher pH, fewer Lactobacillus) with mechanics (friction causing micro-tears), the best use of budget is precise basics and correct placement: a fingertip of cream to the vestibule if that’s where it hurts; a silicone-based lubricant if you lose glide early; gentle, fragrance-free cleansing; and pelvic floor physio if guarding is present. Many people achieve comfort here without escalating spend.
What if you’re unsure whether you’ll need procedures? Build in a pause: run foundations for 6–12 weeks, then review. If dryness flares when you stop moisturiser/lubricant or if insertional sting persists despite great placement, discuss local oestrogen/DHEA technique first. Only then weigh procedures, with realistic timelines (benefits build over weeks, not overnight) and an understanding that maintenance may be needed later.
Safety and evidence guide choices. UK guidance prioritises moisturisers/lubricants and low-dose local oestrogens as first-line options; device-based and regenerative approaches are adjunctive. That matters for both outcomes and spend: start where evidence is strongest and add selectively.
Clinical Context
Who may keep costs lowest? People whose main limiter is vestibular sting/micro-tears and who nail basics: schedule a vaginal moisturiser 2–4 nights weekly, choose a compatible lubricant (silicone-based often gives the longest glide for dyspareunia), and apply creams at the vestibule as well as internally. Many reach comfort without procedures.
Who might budget for add-ons? Those with persistent symptoms after a high-quality foundation + local therapy phase, or mixed GSM features (dryness plus urinary urgency/frequency). Some will consider a short series of energy-based sessions or injectables targeted to symptomatic points; plan for review at 6–12 weeks before deciding on maintenance.
Next steps to plan spend intelligently. Start with the strongest-evidence steps; give them time to work; and use reviews to decide whether to add, switch, or pause. Our pathway pages show how we stage care and the pricing/inclusions so you can budget confidently.
Evidence-Based Approaches
First-line care & self-help (UK): The NHS outlines causes, self-care and when to seek help for vaginal dryness, including moisturiser/lubricant principles and red flags.
Guidelines: The NICE Menopause Guideline (NG23) recommends offering vaginal moisturisers and lubricants and considering low-dose local vaginal oestrogen when GSM affects quality of life; local therapy can be used with or without HRT.
Effectiveness benchmarks: Systematic reviews in the Cochrane Library show local vaginal oestrogens improve dryness, soreness, dyspareunia and vaginal pH versus placebo, helping set realistic expectations and review timing.
Pathophysiology & clinical nuance: Peer-reviewed overviews indexed on PubMed explain GSM mechanisms (thinner epithelium, raised pH, reduced lactobacilli), supporting a foundation-first approach before higher-cost adjuncts.
Regulatory/safety context: UK information on device intended use, vigilance and safety reporting is provided by the national regulator; see the MHRA medical devices pages. ® belongs to its owner.